Werner Martin Michael Schüpbach
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Werner Martin Michael Schüpbach has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Claudio Lino Alberto Bassetti
Department of Neurology, Inselspital, University Hospital and University of Bern, Bern, Switzerland
2 shared publications - Panagiotis Bargiotas
ONISLOS MSCA COFUND, Department of Neurology, Medical School, University of Cyprus, 1678 Nicosia, Cyprus
2 shared publications - Alain Kaelin-Lang
Neurology Department, Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano, Switzerland
1 shared publication - Bernhard Kiss
Department of Urology, University Hospital of Bern, Bern, Switzerland
1 shared publication Claudio Pollo
Department of Neurosurgery, Inselspital, University Hospital Bern, Bern, Switzerland
1 shared publication- Claudio Pollo
Department of Neurosurgery, Bern University Hospital, Inselgruppe AG, Bern, Switzerland
1 shared publication
Latest Publications
- Open Access
- 26 August 2017
- Published by Wiley in Movement Disorders
- Vol. 32 (10) , 1371-1375
Directional leads for deep brain stimulation: Opportunities and challenges
- 26 August 2017
- Published by Wiley in Movement Disorders
- Vol. 32 (10) , 1371-1375
Open AccessDirectional leads for deep brain stimulation: Opportunities and challenges
- Open Access
- 18 July 2017
- Published by Springer Nature in BMC Neurology
- Vol. 17 (1) , 137
Parasomnia overlap disorder, Parkinson’s disease and subthalamic deep brain stimulation: three case reports
Parasomnia overlap disorder (POD) is a distinct parasomnia and characterized by concomitant manifestation of rapid-eye-movement (REM)- and non-REM (NREM)-parasomnias. Although not uncommon among patients with Parkinson’s disease, POD is often under-investigated. This is the first report of patients with PD and features of POD that underwent deep brain stimulation. Our patients exhibited different outcomes of POD features after subthalamic deep brain stimulation. We expect that the reporting of these first patients will open the discussion about the need for more detailed and broad-spectrum assessments regarding parasomnias in PD patients that undergo deep brain stimulation. The implications of our observations are both clinical and neurobiological.
- 18 July 2017
- Published by Springer Nature in BMC Neurology
- Vol. 17 (1) , 137
Open AccessParasomnia overlap disorder, Parkinson’s disease and subthalamic deep brain stimulation: three case reports
Parasomnia overlap disorder (POD) is a distinct parasomnia and characterized by concomitant manifestation of rapid-eye-movement (REM)- and non-REM (NREM)-parasomnias. Although not uncommon among patients with Parkinson’s disease, POD is often under-investigated. This is the first report of patients with PD and features of POD that underwent deep brain stimulation. Our patients exhibited different outcomes of POD features after subthalamic deep brain stimulation. We expect that the reporting of these first patients will open the discussion about the need for more detailed and broad-spectrum assessments regarding parasomnias in PD patients that undergo deep brain stimulation. The implications of our observations are both clinical and neurobiological.
- 1 November 2016
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 32, 12-19
Deep brain stimulation and sleep-wake functions in Parkinson's disease: A systematic review
- 1 November 2016
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 32, 12-19
Deep brain stimulation and sleep-wake functions in Parkinson's disease: A systematic review
- 1 September 2014
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 20 (9) , 1015-1017
Bladder function in patients with dystonia undergoing deep brain stimulation
- 1 September 2014
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 20 (9) , 1015-1017
Bladder function in patients with dystonia undergoing deep brain stimulation
- 2 June 2008
- Published by Taylor & Francis in Aging Health
- Vol. 4 (3) , 225-235
Pramipexole in the Management of Parkinson’s Disease
Parkinson’s disease (PD) is a complex neurodegenerative disease with both motor and nonmotor symptoms. The major clinical symptoms of PD are due to dopamine deficiency caused by the degeneration of nigrostriatal dopaminergic neurons. As a consequence, current treatments remain focused on the dopamine system. Dopamine-replacement therapy with levodopa has been the mainstay of symptomatic treatment of PD for nearly 40 years. However, levodopa-induced motor complications have led many physicians to advocate alternative options for treatment initiation in suitable patients or as an adjunctive therapy in more advanced cases.
- 2 June 2008
- Published by Taylor & Francis in Aging Health
- Vol. 4 (3) , 225-235
Pramipexole in the Management of Parkinson’s Disease
Parkinson’s disease (PD) is a complex neurodegenerative disease with both motor and nonmotor symptoms. The major clinical symptoms of PD are due to dopamine deficiency caused by the degeneration of nigrostriatal dopaminergic neurons. As a consequence, current treatments remain focused on the dopamine system. Dopamine-replacement therapy with levodopa has been the mainstay of symptomatic treatment of PD for nearly 40 years. However, levodopa-induced motor complications have led many physicians to advocate alternative options for treatment initiation in suitable patients or as an adjunctive therapy in more advanced cases.